Table 2.
Treatment outcome in chronic central serous chorioretinopathy patients who received either half‐dose photodynamic therapy or high‐density subthreshold micropulse laser treatment within the PLACE trial.
| Half‐dose PDT (n = 37) | HSML (n = 17) | p‐value | |
|---|---|---|---|
| Mean (SE) | Mean (SD) | ||
| Change in best‐corrected visual acuity (ETDRS letters)* | +1.01 (0.718) | −1.05 (1.004) | 0.103 |
| Change in retinal sensitivity (dB)* | +0.85 (0.307) | +0.70 (0.462) | 0.784 |
| Change in NEI‐VFQ25 composite score (points)* | +0.66 (1.618) | −4.47 (2.252) | 0.071 |
| Change in central retinal thickness (µm)* | −14.8 (6.8) | −7.8 (10.0) | 0.566 |
| Change in subfoveal choroidal thickness (µm)* | −37.8 (30.4) | −21.2 (55.7) | 0.359 |
| Number (%) | Number (%) | p‐value | |
|---|---|---|---|
| Continuity of the external limiting membrane on OCT | 27 (96%) | 8 (67%) | 0.022 |
| Continuity of the ellipsoid zone on OCT | 26 (93%) | 7 (58%) | 0.017 |
*
The mean change estimated by the mixed model between baseline and final visit. ETDRS, Early Treatment of Diabetic Retinopathy Study; HSML, high‐density subthreshold micropulse laser; NEI‐VFQ25, National Eye Institute Visual Functioning Questionnaire 25‐items; OCT, optical coherence tomography; PDT, photodynamic therapy; SE, standard error.